Latest News and Press Releases

Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "Chronic Spontaneous Urticaria Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report...

GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a leading biotechnology company developing an artificial intelligence (AI), GenAI, and machine learning (ML)...

Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Allergy Conjunctivitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global allergy conjunctivitis market...

COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER UNE ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA...

PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris,...

COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...

PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...

COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTERA SON PROGRAMME DE DÉVELOPPEMENT DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) LORS DE L’ÉDITION 2022 DU ALS DRUG DEVELOPMENT SUMMIT Paris, 7 février 2022,...

PRESS RELEASE AB SCIENCE TO PRESENT ON ITS AMYOTROPHIC LATERAL SCLEROSIS (ALS) DEVELOPMENT PROGRAM AT THE 2022 ALS DRUG DEVELOPMENT SUMMIT Paris, 07 February, 2022, 6pm CET AB Science SA (Euronext...

PRESS RELEASE AB SCIENCE HAS BEEN GRANTED AUTHORIZATION TO INITIATE PHASE II STUDY IN PATIENTS WITH SEVERE MAST CELL ACTIVATION SYNDROME BY THE FRENCH HEALTH AUTHORITY (ANSM) Paris, 19 January,...